| No. of patients (%) |
P value*
|
---|
Non-BSI (n = 196) | BSI (n = 26) |
---|
Gender | | | | | |
Male | 141 | (72) | 17 | (65) | 0.492 |
Female | 55 | (28) | 9 | (35) | |
Age ≥ 65 y/o | 127 | (65) | 19 | (73) | 0.402 |
Myeloma subgroup |
IgG | 95 | (48) | 13 | (50) | 0.741 |
IgA | 63 | (32) | 9 | (35) | |
Light chain disease | 29 | (15) | 4 | (15) | |
Other typesa
| 9 | (5) | 0 | (0) | |
Immunoglobulin status |
Severe Ig deficiencyb
| 177 | (90) | 23 | (88) | 0.767 |
Others | 19 | (10) | 3 | (12) | |
ALC count ≥ 1000 (/ul) | 138 | (70) | 17 | (65) | 0.612 |
ISS Stage |
I | 37 | (19) | 1 | (4) | |
II | 64 | (33) | 5 | (19) | |
III | 95 | (48) | 20 | (77) | 0.019 |
ECOG PS >2 | 59 | (30) | 17 | (65) | <.001 |
Hb < 10 (g/dL) | 108 | (55) | 21 | (81) | 0.015 |
Ca > 12.0 (mg/dL) | 14 | (7) | 5 | (19) (58) | 0.038 |
Cr ≥ 2.0 (mg/dL) | 55 | (28) | 15 | | 0.002 |
Induction chemotherapy |
VAD-based | 57 | (29) | 13 | (50) | |
MP-based | 83 | (42) | 7 | (27) | 0.064 |
Othersc
| 30 | (15) | 1 | (4) | |
No | 26 | (13) | 5 | (19) | |
-
Abbreviations: BSI Blood stream infection, IgG Immunoglobulin G, IgA Immunoglobulin A, Ig Immunoglobulin, ALC Absolute lymphocyte count, ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group Performance Status, Hb Hemoglobin, Ca Calcium, Cr Creatinine, VAD Vincristine/doxorubicin/dexamethasone, MP Melphalan/prednisolone
-
aOther types include solitary plasmacytomas and plasma cell leukemia
-
bSevere Ig deficiency is defined as both of the non-myeloma immunoglobulin levels less than one-fourth of lower normal limit
-
cIncluding newer regimens such as thalidomide/dexamethasone (TD), bortezomib/cyclophosphamide/dexamethasone (BCD), bortezomib/dexamethasone (BD), cyclophosphamide/thalidomide/dexamethasone (CTD), and bortezomib/cyclophosphamide/dexamethasone (BTD)
-
*Statistics analysis is used Chi-square or Fisher exact test